Nautilus Biotechnology (NASDAQ:NAUT) Given New $5.00 Price Target at The Goldman Sachs Group
Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) had its price target dropped by stock analysts at The Goldman Sachs Group from $9.00 to $5.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target would suggest a […]